Sumary of Pimavanserin lowers relapse risk in patients with dementia-related psychosis:
- July 21, 2021 3 min read Source/Disclosures Disclosures: Tariot reports conducting independent data monitoring committee, data monitoring committee and safety and data monitoring committee activities for AbbVie;
- serving on advisory boards and participating in AdComm, consultations and independent academic consultations for Acadia Pharmaceuticals;
- performing data and safety monitoring for Avanir Pharmaceuticals, Axome, CME Outfitters and Teva Pharmaceutical Industries;
- serving on an independent data monitoring committee for Genentech;
- Please see the study for all other authors’ relevant financial disclosures.
- Tariot, MD, a clinician, researcher and director of the Banner Alzheimer’s Institute in Phoenix, told Healio Primary Care.
- ” For the HARMONY trial, Tariot and colleagues analyzed results from 392 older adults who met the criteria for dementia and clinical criteria for either Parkinson’s disease dementia, dementia with Lewy bodies, possible or probable Alzheimer’s disease, frontotemporal dementia or vascular dementia.
- Of the remaining participants, Tariot and colleagues reported that a relapse occurred in 13% of participants in the pimavanserin cohort and 28% of participants in the placebo cohort (HR = 0.35;